Clinical trials: Relapsed or Refractory Peripheral T-cell Lymphoma
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Extranodal NK/T-cell Lymphoma, Nasal Type
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
- Trial name
- NCT04405375
- Testing
- gemcitabin, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Beijing Tongren Hospital
Natural Killer T-cell Lymphoma
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural…
- Trial name
- JACKPOT50 (NCT06733051)
- Testing
- Golidocitinib, Benmelstobart
- Where
- 2 sites in China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00078949
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 849 people
- Sponsor
- NCIC Clinical Trials Group
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell…
- Trial name
- NCT05934513
- Testing
- GFH009
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
B-Cell Lymphoma
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma.
- Trial name
- NCT00338494
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University
Lymphoma
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts.
- Trial name
- NCT00771472
- Testing
- vorinostat
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
T Cell Lymphoma
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Patients meeting specific inclusion and exclusion criteria will be enrolled in two stages, 19 patients in Stage 1 and 36 patients in Stage 2.
- Trial name
- NCT00798096
- Testing
- Fostamatinib Disodium
- Where
- 10 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
This is a single-arm, open, multi-center, phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection in Relapsed or refractory peripheral t-cell and NK/T-cell lymphoma.
- Trial name
- NCT03776279
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 106 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-Hodgkin's Lymphoma, Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
This study aims to evaluate the safety and efficacy of autologous γδT cells in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphoblastic leukemia (CLL) and peripheral T cell lymphoma (PTCL)…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphoblastic Leukemia, Peripheral T Cell Lymphoma
- Trial name
- NCT04028440
- Testing
- Autologous γδT cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas. UCN-01 inhibits the growth of several different tumor cells, and, in laboratory studies, it has worked…
- Trial name
- NCT00082017
- Testing
- UCN-01 (7-hydroxystaurosporine)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment.
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides
- Trial name
- NCT03278782
- Testing
- Pembrolizumab, Romidepsin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
NK T-Cell Lymphoma, CART Therapy
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural…
- Conditions
- NK T-Cell Lymphoma, CART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- Trial name
- NCT06732492
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00750009
- Testing
- educational intervention
- Where
- 4 sites in United States
- Volunteers
- 583 people
- Sponsor
- Case Comprehensive Cancer Center
Peripheral T-cell Lymphoma
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Japanese patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- NCT01435863
- Testing
- SP-02L (darinaparsin for injection)
- Where
- 4 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Solasia Pharma K.K.
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects.
- Conditions
- Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
- Trial name
- NCT04217317
- Testing
- CPI 613, Bendamustine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
PTCL, NK T-Cell Lymphoma
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in…
- Trial name
- NCT07639879
- Testing
- TR115, Investigator's Choice
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tarapeutics Science Inc.
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma
- Trial name
- NCT00005950
- Testing
- nelarabine
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat)…
- Trial name
- COMBOSTAT (NCT00837174)
- Testing
- Vorinostat in combination with Bortezomib
- Sponsor
- The Methodist Hospital Research Institute